Aktis Oncology CEO to Present at BofA Health Care Conference
Event summary
- Aktis Oncology CEO Matthew Roden to present at BofA Securities Health Care Conference on May 13, 2026.
- Live webcast available via Aktis Investors section; replay accessible for 90 days post-event.
- Aktis focuses on expanding targeted radiopharmaceuticals to broader patient populations.
- AKY-1189 and AKY-2519 are clinical-stage pipeline programs targeting multiple tumor types.
- Discovery collaboration with Eli Lilly to develop novel radioconjugates outside Aktis’ proprietary pipeline.
The big picture
Aktis Oncology is positioning itself as a key player in the targeted radiopharmaceutical space, aiming to address unmet needs across multiple solid tumors. The company’s proprietary platform and strategic collaborations, such as with Eli Lilly, highlight its focus on expanding the reach of radiopharmaceutical treatments beyond current limitations. The upcoming presentation at the BofA Securities Health Care Conference provides an opportunity for the company to showcase its progress and strategic vision to investors and industry stakeholders.
What we're watching
- Clinical Progress
- The pace at which Aktis advances AKY-1189 and AKY-2519 through clinical trials will determine its competitive positioning in the radiopharmaceutical space.
- Strategic Partnerships
- The success of the Eli Lilly collaboration in developing novel radioconjugates could expand Aktis’ pipeline and validate its platform technology.
- Market Differentiation
- How Aktis’ miniprotein radioconjugate platform performs against existing radiopharmaceutical technologies will shape its long-term market potential.
Related topics